title: [Octreotide in the treatment of angiodysplasia in patients with advanced chronic renal failure].
abstract: Angiodysplasia is an important cause of gastrointestinal bleeding in patients with chronic renal failure. Octreotide, a long-acting synthetic somatostatin analogue that reduces splachnic blood flow have been used to treat esophageal varicose hemorrhage, but its efficacy for bleeding vascular ecstasies is awaiting support. We present three patients with chronic renal failure (two with diabetic nephropaty and the third with mesangiocapilar glomerulonephritis and hepatic cirrosis), seric creatinine 3-4,5 mg/dl, and recurrent gastrointestinal bleeding due to diffuse angiodysplasia and vascular ecstasies, diagnosed by oral endoscopy, colonoscopy and video capsule. They all were treated with octreotide, administered subcutanesly 0.1 mg twice a day for six months, with significantly decreased blood requirements in all of them, as well as the occurrence of bleeding episodes. It was well tolerated and none side-effects occurred in any subject. In our experience, octreotide is an effective and safe drug in bleeding angiodysplasia and ecstasies vascular of the gastrointestinal tract in patients with chronic renal failure, and it may be a good option especially in patients who are not candidates for surgery or endoscopic treatment due to inaccessible sites, spread of the lesion, old age and/or concomitant disorders.
authors.affiliation: Servicio de Nefrología, Hospital Universitario Virgen del Rocío, Sevilla. mariana76@terra.es
authors.forename: M
authors.initials: M
authors.lastname: Rivera
authors.forename: J
authors.initials: J
authors.lastname: Lucero
authors.forename: A
authors.initials: A
authors.lastname: Guerrero
authors.forename: J L
authors.initials: JL
authors.lastname: Márquez
authors.forename: R
authors.initials: R
authors.lastname: Montes
authors.forename: M
authors.initials: M
authors.lastname: Suñer
authors.forename: A
authors.initials: A
authors.lastname: Ruiz
authors.forename: M A
authors.initials: MA
authors.lastname: Valdivia
authors.forename: J
authors.initials: J
authors.lastname: Mateos
mesh_terms: D000328:Adult; D000368:Aged; D016888:Angiodysplasia / Q000188:drug therapy* / Q000209:etiology; D001803:Blood Transfusion; D003113:Colonoscopy; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000150:complications; D004724:Endoscopy; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000628:therapy; D015432:Glomerulonephritis, Membranoproliferative / Q000150:complications; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D008104:Liver Cirrhosis, Alcoholic / Q000150:complications; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D006435:Renal Dialysis
chemical_list: D015282:Octreotide